Since PDTC, apart from potent NF-κB inhibitory properties and direct cytotoxic effect against tumor cells, manifests strong anti-angiogenic effects (31,40), its addition to sulindac-based therapy could reveal stronger antitumor activity in vivo than those observed in ovarian cancer cell cultures in vitro. This evidence concerns the gene NFKB1 and ovarian cancer.